Literature DB >> 27754870

Transgenic Expression of the Mitochondrial Chaperone TNFR-associated Protein 1 (TRAP1) Accelerates Prostate Cancer Development.

Sofia Lisanti1,2, David S Garlick1, Kelly G Bryant1,2, Michele Tavecchio1,2, Gordon B Mills3, Yiling Lu3, Andrew V Kossenkov4, Louise C Showe4,5, Lucia R Languino1,6, Dario C Altieri7,2.   

Abstract

Protein homeostasis, or proteostasis, is required for mitochondrial function, but its role in cancer is controversial. Here we show that transgenic mice expressing the mitochondrial chaperone TNFR-associated protein 1 (TRAP1) in the prostate develop epithelial hyperplasia and cellular atypia. When examined on a Pten+/- background, a common alteration in human prostate cancer, TRAP1 transgenic mice showed accelerated incidence of invasive prostatic adenocarcinoma, characterized by increased cell proliferation and reduced apoptosis, in situ Conversely, homozygous deletion of TRAP1 delays prostatic tumorigenesis in Pten+/- mice without affecting hyperplasia or prostatic intraepithelial neoplasia. Global profiling of Pten+/--TRAP1 transgenic mice by RNA sequencing and reverse phase protein array reveals modulation of oncogenic networks of cell proliferation, apoptosis, cell motility, and DNA damage. Mechanistically, reconstitution of Pten+/- prostatic epithelial cells with TRAP1 increases cell proliferation, reduces apoptosis, and promotes cell invasion without changes in mitochondrial bioenergetics. Therefore, TRAP1 is a driver of prostate cancer in vivo and an "actionable" therapeutic target.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  chaperone; heat shock protein 90 (Hsp90); mitochondria; prostate cancer; protein folding

Mesh:

Substances:

Year:  2016        PMID: 27754870      PMCID: PMC5122790          DOI: 10.1074/jbc.M116.745950

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  36 in total

1.  SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression.

Authors:  Zhihu Ding; Chang-Jiun Wu; Gerald C Chu; Yonghong Xiao; Dennis Ho; Jingfang Zhang; Samuel R Perry; Emma S Labrot; Xiaoqiu Wu; Rosina Lis; Yujin Hoshida; David Hiller; Baoli Hu; Shan Jiang; Hongwu Zheng; Alexander H Stegh; Kenneth L Scott; Sabina Signoretti; Nabeel Bardeesy; Y Alan Wang; David E Hill; Todd R Golub; Meir J Stampfer; Wing H Wong; Massimo Loda; Lorelei Mucci; Lynda Chin; Ronald A DePinho
Journal:  Nature       Date:  2011-02-02       Impact factor: 49.962

2.  Preclinical characterization of mitochondria-targeted small molecule hsp90 inhibitors, gamitrinibs, in advanced prostate cancer.

Authors:  Byoung Heon Kang; Markus D Siegelin; Janet Plescia; Christopher M Raskett; David S Garlick; Takehiko Dohi; Jane B Lian; Gary S Stein; Lucia R Languino; Dario C Altieri
Journal:  Clin Cancer Res       Date:  2010-09-28       Impact factor: 12.531

3.  Control of tumor bioenergetics and survival stress signaling by mitochondrial HSP90s.

Authors:  Young Chan Chae; M Cecilia Caino; Sofia Lisanti; Jagadish C Ghosh; Takehiko Dohi; Nika N Danial; Jessie Villanueva; Stefano Ferrero; Valentina Vaira; Luigi Santambrogio; Silvano Bosari; Lucia R Languino; Meenhard Herlyn; Dario C Altieri
Journal:  Cancer Cell       Date:  2012-09-11       Impact factor: 31.743

4.  Mitochondrial Hsp90 is a ligand-activated molecular chaperone coupling ATP binding to dimer closure through a coiled-coil intermediate.

Authors:  Nuri Sung; Jungsoon Lee; Ji-Hyun Kim; Changsoo Chang; Andrzej Joachimiak; Sukyeong Lee; Francis T F Tsai
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-29       Impact factor: 11.205

5.  Fast gapped-read alignment with Bowtie 2.

Authors:  Ben Langmead; Steven L Salzberg
Journal:  Nat Methods       Date:  2012-03-04       Impact factor: 28.547

6.  Development of a mitochondria-targeted Hsp90 inhibitor based on the crystal structures of human TRAP1.

Authors:  Changwook Lee; Hye-Kyung Park; Hanbin Jeong; Jaehwa Lim; An-Jung Lee; Keun Young Cheon; Chul-Su Kim; Ajesh P Thomas; Boram Bae; Nam Doo Kim; Seong Heon Kim; Pann-Ghill Suh; Ja-Hyoung Ryu; Byoung Heon Kang
Journal:  J Am Chem Soc       Date:  2015-03-30       Impact factor: 15.419

Review 7.  TRAP-1, the mitochondrial Hsp90.

Authors:  Dario C Altieri; Gary S Stein; Jane B Lian; Lucia R Languino
Journal:  Biochim Biophys Acta       Date:  2011-08-22

Review 8.  Mitochondrial matrix proteases as novel therapeutic targets in malignancy.

Authors:  C A Goard; A D Schimmer
Journal:  Oncogene       Date:  2013-06-17       Impact factor: 9.867

9.  mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways.

Authors:  Pradip K Majumder; Phillip G Febbo; Rachel Bikoff; Raanan Berger; Qi Xue; Louis M McMahon; Judith Manola; James Brugarolas; Timothy J McDonnell; Todd R Golub; Massimo Loda; Heidi A Lane; William R Sellers
Journal:  Nat Med       Date:  2004-05-23       Impact factor: 53.440

10.  Aberrantly upregulated TRAP1 is required for tumorigenesis of breast cancer.

Authors:  Bo Zhang; Jing Wang; Zhen Huang; Peng Wei; Ying Liu; Junfeng Hao; Lijing Zhao; Fenglin Zhang; Yaping Tu; Taotao Wei
Journal:  Oncotarget       Date:  2015-12-29
View more
  13 in total

Review 1.  Mitochondrial dynamics and metastasis.

Authors:  Dario C Altieri
Journal:  Cell Mol Life Sci       Date:  2018-11-10       Impact factor: 9.261

2.  Myc-mediated transcriptional regulation of the mitochondrial chaperone TRAP1 controls primary and metastatic tumor growth.

Authors:  Ekta Agarwal; Brian J Altman; Jae Ho Seo; Jagadish C Ghosh; Andrew V Kossenkov; Hsin-Yao Tang; Shiv Ram Krishn; Lucia R Languino; Dmitry I Gabrilovich; David W Speicher; Chi V Dang; Dario C Altieri
Journal:  J Biol Chem       Date:  2019-05-16       Impact factor: 5.157

3.  HSP90-Specific nIR Probe Identifies Aggressive Prostate Cancers: Translation from Preclinical Models to a Human Phase I Study.

Authors:  Takuya Osada; Erika J Crosby; Kensuke Kaneko; Joshua C Snyder; Joshua D Ginzel; Chaitanya R Acharya; Xiao-Yi Yang; Thomas J Polascik; Ivan Spasojevic; Rendon C Nelson; Amy Hobeika; Zachary C Hartman; Leonard M Neckers; Andre Rogatko; Philip F Hughes; Jiaoti Huang; Michael A Morse; Timothy Haystead; H Kim Lyerly
Journal:  Mol Cancer Ther       Date:  2021-10-21       Impact factor: 6.261

Review 4.  TRAP1 Chaperones the Metabolic Switch in Cancer.

Authors:  Laura A Wengert; Sarah J Backe; Dimitra Bourboulia; Mehdi Mollapour; Mark R Woodford
Journal:  Biomolecules       Date:  2022-06-04

Review 5.  Defining the Hallmarks of Metastasis.

Authors:  Danny R Welch; Douglas R Hurst
Journal:  Cancer Res       Date:  2019-05-03       Impact factor: 12.701

Review 6.  The Mitochondrial Unfolded Protein Response as a Non-Oncogene Addiction to Support Adaptation to Stress during Transformation in Cancer and Beyond.

Authors:  Timothy C Kenny; Giovanni Manfredi; Doris Germain
Journal:  Front Oncol       Date:  2017-07-26       Impact factor: 6.244

7.  Cytosolic Hsp90α and its mitochondrial isoform Trap1 are differentially required in a breast cancer model.

Authors:  Evangelia Vartholomaiou; Marta Madon-Simon; Stéphane Hagmann; Guillaume Mühlebach; Wolfgang Wurst; Thomas Floss; Didier Picard
Journal:  Oncotarget       Date:  2017-03-14

Review 8.  TRAP1 Regulation of Cancer Metabolism: Dual Role as Oncogene or Tumor Suppressor.

Authors:  Danilo Swann Matassa; Ilenia Agliarulo; Rosario Avolio; Matteo Landriscina; Franca Esposito
Journal:  Genes (Basel)       Date:  2018-04-05       Impact factor: 4.096

9.  A Mitochondrial-targeted purine-based HSP90 antagonist for leukemia therapy.

Authors:  Kelly G Bryant; Young Chan Chae; Rogelio L Martinez; John C Gordon; Khaled M Elokely; Andrew V Kossenkov; Steven Grant; Wayne E Childers; Magid Abou-Gharbia; Dario C Altieri
Journal:  Oncotarget       Date:  2017-12-11

Review 10.  Succinate: An initiator in tumorigenesis and progression.

Authors:  Ting Zhao; Xianmin Mu; Qiang You
Journal:  Oncotarget       Date:  2017-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.